Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis
- 268 Downloads
The efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemic patients with chronic kidney disease.
We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemic patients with CKD.
Four studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96–1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45–0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07–13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD − 76.1 μg/L; 95% CI − 91.8 to − 60.3, p < 0.00001) and ferritin (WMD − 63.6 μg/L; 95% CI − 96.6 to − 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups.
Daprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemic patients with chronic kidney disease in the future.
KeywordsMeta-analysis Daprodustat Chronic kidney disease
Thanks Yuhua He, Guoshuan Zhu, and Lijie Li for useful suggestions.
Compliance with ethical standards
Conflict of interest
The authors have declared that no conflict of interest exists.
Research involving human and animal participants
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was obtained from all individual participants included the study.
- 12.Horwich TB, Fonarow GC, Hamilton MA et al (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 8(4):235–236Google Scholar
- 17.Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie 5(2):S38Google Scholar